Nano-sized cationic polymeric magnetic liposomes significantly improves drug delivery to the brain in rats

Journal of Drug Targeting

Volumn 20, Issue 5, 2012, Pages 416-421

  Zhao, Ming ^a   Chang, Jin ^b   Fu, Xiangping ^a   Liang, Chao ^a   Liang, Shuli ^a   Yan, Runmin ^a   Li, Anmin ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b TIANJIN UNIVERSITY   (China)

Author keywords

Brain; Magnetic liposome; Paclitaxel; Polymeric liposome

Indexed keywords

CATIONIC POLYMERIC MAGNETIC LIPOSOME; LIPOSOME; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; BRAIN CORTEX; BRAIN FUNCTION; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; INTERNAL CAROTID ARTERY; MAGNETIC FIELD; MALE; NANOANALYSIS; NANOFABRICATION; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD-BRAIN BARRIER; BRAIN; CATIONS; DRUG DELIVERY SYSTEMS; FERROCYANIDES; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; LIPOSOMES; MAGNETICS; MALE; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; STAINING AND LABELING; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84861070748     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2011.651726     Document Type: Article

References (24)

1. Aksungur P, Sungur A, Unal S, Iskit AB, Squier CA, Senel S. (2004). Chitosan delivery systems for the treatment of oral mucositis: In vitro and in vivo studies. J Control Release, 98, 269-279. (Pubitemid 38950736)
2. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Lübbe AS. (2000). Locoregional cancer treatmentwith magnetic drug targeting. Cancer Res, 60, 6641-6648.
3. Alexiou C, Jurgons R, Seliger C, Brunke O, Iro H, Odenbach S. (2007). Delivery of superparamagnetic nanoparticles for local chemotherapy after intraarterial infusion and magneticdrug targeting. Anticancer Res, 27, 2019-2022. (Pubitemid 46954718)
4. Brigger I, Dubernet C, Couvreur P. (2002). Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev, 54, 631-651. (Pubitemid 35247520)
5. Dobson J. (2006). Magnetic micro- and nano-particle-based targeting for drug and gene delivery. Nanomedicine (Lond), 1, 31-37.
6. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhänel M, Spruss T, Bernhardt G, Graeff C, Färber L, Gschaidmeier H, Buschauer A, Fricker G. (2002). Transport of paclitaxel (Taxol) across the bloodbrain barrier in vitro and in vivo. J Clin Invest, 110, 1309-1318. (Pubitemid 35285757)
7. Gurney JG, Kadan-Lottick N. (2001). Brain and other central nervous system tumors: Rates, trends, and epidemiology. Curr Opin Oncol,13, 160-166. (Pubitemid 32433971)
8. Hillaireau H, Couvreur P. (2009). Nanocarriers' entry into the cell: Relevance to drug delivery. Cell Mol Life Sci, 66, 2873-2896.
9. Hollins AJ, Omidi Y, Benter IF, Akhtar S. (2007). Toxicogenomics of drug delivery systems: Exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. J Drug Target, 15, 83-88. (Pubitemid 47161335)
10. Jaishri Blakeley. (2008). Drug delivery to brain tumors. Curr Neurol Neurosci Rep, 8, 235-2341.
11. Lenaerts V, Couvreur P, Christiaens-Leyh D, Joiris E, Roland M, Rollman B, Speiser P. (1984). Degradation of poly (isobutylcyanoacrylate) nanoparticles. Biomaterials, 5, 65-68.
12. Liang XF, Wang HJ, Luo H, Tian H, Zhang BB, Hao LJ, Teng JI, Chang J. (2008). Characterization of novel multifunctional cationicpolymeric liposomes formed from octadecyl quaternized carboxymethyl chitosan/cholesterol and drug encapsulation. Langmuir, 24, 7147-7153.
13. Lübbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW, Huhn D. (1996). Preclinical experiences with magnetic drug targeting: Tolerance and efficacy. Cancer Res, 56, 4694-4701. (Pubitemid 26338072)
14. Lübbe AS, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K, Matthias M, Dörken B, Herrmann F, Gürtler R, Hohenberger P, Haas N, Sohr R, Sander B, Lemke AJ, Ohlendorf D, Huhnt W, Huhn D. (1996). Clinical experiences with magnetic drug targeting: A phase I study with 4'-epidoxorubicin in 14 patients with advancedsolid tumors. Cancer Res, 56, 4686-4693. (Pubitemid 26338071)
15. McBain SC, Yiu HH, Dobson J. (2008). Magnetic nanoparticles for gene and drug delivery. Int J Nanomedicine, 3, 169-180. (Pubitemid 352037850)
16. Omidi Y, Hollins AJ, Drayton RM, Akhtar S. (2005). Polypropylenimine dendrimer-induced gene expression changes: The effect of complexation with DNA, dendrimer generation and cell type. J Drug Target, 13, 431-443. (Pubitemid 43084544)
17. Park J, Lu W. (2009). Interaction of nanoparticles with lipid layers. Phys Rev E Stat Nonlin Soft Matter Phys, 80, 021607.
18. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. (2009). Getting into the brain: Approaches to enhance brain drug delivery. CNS Drugs, 23, 35-58.
19. Prabaharan M, Mano JF. (2005). Chitosan-based particles as controlled drug delivery systems. Drug Deliv, 12, 41-57. (Pubitemid 40066260)
20. Rivière C, Martina MS, Tomita Y, Wilhelm C, Tran Dinh A, Ménager C, Pinard E, Lesieur S, Gazeau F, Seylaz J. (2007). Magnetic targeting of nanometric magnetic fluid loaded liposomes to specific brainintravascular areas: A dynamic imaging study in mice. Radiology, 244, 439-448. (Pubitemid 47080875)
21. Roiter Y, Ornatska M, Rammohan AR, Balakrishnan J, Heine DR, Minko S. (2009). Interaction of lipid membrane with nanostructured surfaces. Langmuir, 25, 6287-6299.
22. Schröder U, Sabel BA. (1996). Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res, 710, 121-124. (Pubitemid 26082045)
23. Sharon KP, Suzanne LC, James MG. (1999). Distribution of small magnetic particles in brain tumor-bearing rats. J Neurooncol, 41, 99-105.
24. Widder KJ, Senyel AE, Scarpelli GD. (1978). Magnetic microspheres: A model system of site specific drug delivery in vivo. Proc Soc Exp Biol Med, 158, 141-146. (Pubitemid 8386575)